Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study
04 mai 2021 08h00 HE
|
Vaxart, Inc.
Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study...
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
03 mai 2021 17h06 HE
|
Vaxart, Inc.
Vaxart oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa,...
Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update
03 mai 2021 08h00 HE
|
Vaxart, Inc.
Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/IIFour clinical...
Vaxart to Present at the World Vaccine Congress Washington 2021
29 avr. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
26 avr. 2021 08h00 HE
|
Vaxart, Inc.
Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE...
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
23 avr. 2021 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
22 avr. 2021 08h00 HE
|
Vaxart, Inc.
Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection SOUTH SAN...
Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by...
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 16h01 HE
|
Vaxart, Inc.
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021Cash and cash equivalents of $126.9 million as of December 31,...
Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
24 févr. 2021 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than...